7. Conclusion Finally, we would like to state that if we continue to use genetic vaccines such aspseudouridinated mRNAs and mRNA-LNP platforms [46,103], there will be further risks like thosedescribed in this review. It should also be stressed that the issues discussed here are matters thatpertain to all organ transplants, including bone marrow transplants, and not just blood products. Theimpact of these genetic vaccines on blood products and the actual damage caused by them areunknown at present. Therefore, in order to avoid these risks and prevent further expansion of bloodcontamination and complication of the situation, we strongly request that the vaccination campaignusing genetic vaccines be suspended and that a harm–benefit assessment be carried out as early aspossible, as called for by Fraiman et al. and Polykretis et al. [27,31–33]. As we have repeatedly stated,the health injuries caused by genetic vaccination are already extremely serious, and it is high timethat countries and relevant organizations take concrete steps together to identify the risks and tocontrol and resolve them.
